TransCode Therapeutics (RNAZ) announced that it has received notice from the Nasdaq Stock Market that the company has regained compliance with Listing Rules 5550(a)(2) and 5550(b)(1), the Exchange’s minimum bid price and shareholders’ equity rules, respectively. The company has also resolved the violation regarding Listing Rule 5635 by obtaining shareholder ratification of a July 2024 equity transaction. As a result, the company’s shares will remain listed on the Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the company will be subject to a Discretionary Panel Monitor through December 24, 2025.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RNAZ:
- Transcode announces SRC approved third cohort in TTX-MC138 clinical trial
- Transcode Therapeutics Inc trading halted, news pending
- TransCode Therapeutics Raises $8M in Private Placement
- TransCode Therapeutics Announces Reverse Stock Split
- Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
